Transparency Guidelines for Relationships between Corporate Activities and Medical Institutions Q14. What are the research and development expenses, etc.?

Expenses incurred for joint research and commissioned research with universities and other academia, as well as when clinical trials (development clinical trials) and post-marketing studies are commissioned to medical institutions, etc. It is the responsibility of R&D-oriented pharmaceutical companies to contribute to the medical community through the development of innovative new drugs. This activity cannot be carried out by a pharmaceutical company alone, and cannot be done without the cooperation of many medical professionals and patients. Medical evaluations of joint research, contract research, clinical trials (development trials), etc. are conducted neutrally and impartially by research institutes and medical professionals in their respective fields of expertise. In addition, post-marketing surveillance, reporting of adverse drug reactions and infectious disease cases, etc. are the obligations of pharmaceutical companies under strict public regulations such as the GPSP and GVP ordinances, and are conducted with the cooperation of medical institutions and others.